Use of sCD14 or its fragments or derivatives for risk stratification, diagnosis and prognosis
AssigneePHC Corporation
InventorEberhard Spanuth
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for diagnosis of a cardiovascular disease or condition or atherosclerosis and for a method for evaluating the risk of a subject of developing the same. Methods are further provided for evaluating a subject's risk of mortality, for evaluating whether a subject will benefit from a certain treatment or whether a subject needs to be hospitalized or whether a subject may be discharged. The present invention provides sCD14 or a fragment or derivative thereof (including in particular sCD14-ST) as a novel marker for cardiovascular risk in general, more specifically as a marker for cardiovascular disease or condition, or atherosclerosis.
Claims4
A method of diagnosing and treating a cardiovascular disease or condition in a patient, said method comprising:
- a. obtaining a blood, plasma, or serum sample from a human patient;
- b. detecting sCD14-ST present in the blood, plasma, or serum sample, or having sCD14-ST detected in the blood, plasma, or serum sample;
- c. diagnosing the patient with a cardiovascular disease or condition when the presence of sCD14-ST in the blood, plasma, or serum sample is detected;
- and
- d. administering an appropriate treatment to the diagnosed patient, wherein an amount of sCD14-ST in the diagnosed patient to be administered is 345 pg/ml or higher, and wherein the appropriate treatment is selected from the group consisting of antibiotics, probiotics, and lactulose;
- wherein the patient shows symptoms of one or more cardiovascular diseases or conditions selected from the group consisting of chronic heart failure and angina pectoris;
- and
- wherein the sCD14-ST has an apparent molecular weight of 13±2 kDa when electrophoresed under non-reducing conditions.
A method of treating a cardiovascular disease or condition in a patient, said method comprising:
- a. obtaining a blood, plasma, or serum sample from a human patient;
- b. detecting sCD14-ST present in the blood, plasma, or serum sample, or having sCD14-ST detected in the blood, plasma, or serum sample;
- and
- c. administering an appropriate treatment to a patient showing an amount of sCD14-ST of 345 pg/ml or higher, and wherein the appropriate treatment is selected from the group consisting of antibiotics, probiotics, and lactulose;
- wherein the patient shows symptoms of one or more cardiovascular diseases or conditions selected from the group consisting of chronic heart failure and angina pectoris, and
- wherein the sCD14-ST has an apparent molecular weight of 13±2 kDa when electrophoresed under non-reducing conditions.
Dependencies are inferred from the claim text.